drugset
drugset / Trial / NCT00759122

Electroencephalography (EEG) Biomarkers of Response in Depression

NCT00759122 ↗

Phase 4 Completed 44 enrolled University of California, Los Angeles Medtronic - MITG · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

There are two specific aims of this project: 1. To identify physiologic indicators of venlafaxine treatment response using quantitative EEG (QEEG) cordance, and to determine if cordance changes are specifically associated with response to venlafaxine 2. To identify predictors of placebo response in major depression using QEEG cordance/bispectral index (BIS) and neuropsychological testing

Timeline

Start
2002-11
Primary completion
2005-11
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Venlafaxine Small molecule 150 mg —

Indications

major depressive disorder